Literature DB >> 34926225

Modified HE4, CA125, and ROMA cut-off values and predicted probability of ovarian tumor in Chinese patients.

Xingping Zhao1, Meidan Zhao1, Bingsi Gao1, Aiqian Zhang1, Dabao Xu1.   

Abstract

BACKGROUND: Most prior studies investigating the risk of ovarian malignancy algorithm (ROMA) with cancer antigen 125 (CA125) and human epididymis protein 4 (HE4) have involved Caucasian population or other populations. To date, there have been no unique calculations of predicted probability (PP) risk specifically for Chinese populations to help physicians in primary care settings.
METHODS: A group of 534 women with ovarian tumor diagnoses were enrolled and serum HE4 and CA125 were measured in each individual. Modified cut-off values were obtained by maximizing area under the curve (AUC) values and adjusted by using logistic regression with corresponding sensitivity (SN), specificity (SP), Youden index (YI), positive predictive value (PPV), and negative predictive value (NPV).
RESULTS: By utilizing the ideal PPV, NPV, and AUC values, in premenopausal women modified HE4, CA125, ROMA, and PP cut-off values were 73.87 pmol/L, 61.60 U/mL, 18.47%, and 0.168, respectively. The same test values for postmenopausal women were 120.90 pmol/L, 76.21 U/mL, 26.48%, and 0.485, respectively. The SN for HE4 with the modified cut-off value was significantly lower than that for CA125 (P=0.040) in premenopausal women and lower than that for ROMA (P=0.001) and PP (P=0.044) in postmenopausal women. The AUC values for CA125, ROMA, and PP were all significantly higher than that for HE4 (P=0.006, 0.007, and 0.002, respectively) in postmenopausal women.
CONCLUSIONS: The modified cut-off values for HE4, CA125, ROMA, and PP with ideal SN, SP, YI, NPV, PPV were useful of ruling out ovarian malignancy among both pre- and post-menopausal women. In premenopausal women modified HE4, CA125, ROMA, and PP cut-off values were 73.87 pmol/L, 61.60 U/mL, 18.47%, and 0.168, respectively and in postmenopausal women were 120.90 pmol/L, 76.21 U/mL, 26.48%, and 0.485, respectively. 2021 Gland Surgery. All rights reserved.

Entities:  

Keywords:  Ovarian tumor (OC); cut-off values; predicted probability model

Year:  2021        PMID: 34926225      PMCID: PMC8637074          DOI: 10.21037/gs-21-666

Source DB:  PubMed          Journal:  Gland Surg        ISSN: 2227-684X


  23 in total

1.  The Risk of Ovarian Malignancy Algorithm (ROMA) as a Predictive Marker of Peritoneal Dissemination in Epithelial Ovarian Cancer Patients.

Authors:  Yuji Ikeda; Kosei Hasegawa; Akira Kurosaki; Akiko Miyara; Tatsuya Hanaoka; Daisuke Shintani; Yuichi Imai; Tadaaki Nishikawa; Katsutoshi Oda; Keiichi Fujiwara
Journal:  Oncol Res Treat       Date:  2015-05-19       Impact factor: 2.825

2.  Evaluation of HE4, CA-125, Risk of Ovarian Malignancy Algorithm (ROMA) and Risk of Malignancy Index (RMI) in the Preoperative Assessment of Patients with Adnexal Mass.

Authors:  Khawla Al Musalhi; Manal Al Kindi; Faiza Al Aisary; Fatma Ramadhan; Thuraya Al Rawahi; Khalsa Al Hatali; Waad-Allah Mula-Abed
Journal:  Oman Med J       Date:  2016-09

3.  Cancer statistics, 2014.

Authors:  Rebecca Siegel; Jiemin Ma; Zhaohui Zou; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2014-01-07       Impact factor: 508.702

4.  Development of a multimarker assay for differential diagnosis of benign and malignant pelvic masses.

Authors:  Xinliang Chen; Hui Zhou; Rui Chen; Jian He; Ying Wang; Lisi Huang; Longqiaozi Sun; Chaohui Duan; Xiaohong Luo; Haiyan Yan
Journal:  Clin Chim Acta       Date:  2014-11-15       Impact factor: 3.786

5.  Diagnostic performances of HE4 and CA125 for the detection of ovarian cancer from patients with various gynecologic and non-gynecologic diseases.

Authors:  Yongjung Park; Jong-Han Lee; Duck Jin Hong; Eun Young Lee; Hyon-Suk Kim
Journal:  Clin Biochem       Date:  2011-04-22       Impact factor: 3.281

6.  Modification of cut-off values for HE4, CA125 and the ROMA algorithm for early-stage epithelial ovarian cancer detection: Results from 1021 cases in South China.

Authors:  Ying Xu; Rihui Zhong; Jian He; Rui Ding; Haixiong Lin; Yawen Deng; Lijun Zhou; Xiaohui Li; Junyi Jiang; Yunwen Bao; Xiaohong Luo; Chaohui Duan
Journal:  Clin Biochem       Date:  2015-08-15       Impact factor: 3.281

7.  HE4, CA125 and risk of ovarian malignancy algorithm (ROMA) as diagnostic tools for ovarian cancer in patients with a pelvic mass: An Italian multicenter study.

Authors:  Cesare Romagnolo; Antonette E Leon; Aline S C Fabricio; Martina Taborelli; Jerry Polesel; Lino Del Pup; Agostino Steffan; Silvia Cervo; Antonella Ravaggi; Laura Zanotti; Elisabetta Bandiera; Franco E Odicino; Novella Scattolo; Elisa Squarcina; Christine Papadakis; Tiziano Maggino; Massimo Gion
Journal:  Gynecol Oncol       Date:  2016-01-19       Impact factor: 5.482

8.  Diagnostic accuracy of serum HE4, CA125 and ROMA in patients with ovarian cancer: a meta-analysis.

Authors:  Jiwen Wang; Jia Gao; Hongwen Yao; Zongyong Wu; Minjie Wang; Jun Qi
Journal:  Tumour Biol       Date:  2014-03-14

9.  Comparison of HE4, CA125, and Risk of Ovarian Malignancy Algorithm in the Prediction of Ovarian Cancer in Korean Women.

Authors:  Hye Yon Cho; Sung Ho Park; Young Han Park; Hong Bae Kim; Jung Bae Kang; Seung Hwa Hong; Min Sun Kyung
Journal:  J Korean Med Sci       Date:  2015-11-30       Impact factor: 2.153

Review 10.  Identifying Ovarian Cancer in Symptomatic Women: A Systematic Review of Clinical Tools.

Authors:  Garth Funston; Victoria Hardy; Gary Abel; Emma J Crosbie; Jon Emery; Willie Hamilton; Fiona M Walter
Journal:  Cancers (Basel)       Date:  2020-12-08       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.